| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 23.499 | 12.251 | 811 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 23.499 | 12.251 | 811 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Expenses - EUR | 28.856 | 13.402 | 1.724 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit/Loss - EUR | -5.357 | -1.151 | -914 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit/Loss - EUR | -6.062 | -1.396 | -938 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Employees | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Iris Ana Best Pharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 190 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 3.388 | 7.779 | 393 | 361 | 354 | 348 | 340 | 341 | 340 | 338 |
| Inventories | 3.173 | 677 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 4.792 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 215 | 2.310 | 393 | 361 | 354 | 348 | 340 | 341 | 340 | 338 |
| Shareholders Funds | -17.129 | -18.350 | -18.978 | -18.629 | -18.269 | -17.922 | -17.525 | -17.579 | -17.526 | -17.428 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 20.707 | 26.129 | 19.370 | 18.991 | 18.623 | 18.270 | 17.865 | 17.920 | 17.866 | 17.766 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Iris Ana Best Pharm Srl